CDXSNasdaqIndustrial Organic ChemicalsFiscal year ends December 31
CODEXIS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.32+0.08 (+6.45%)
Close on Oct 19, 2026
- Market cap
- $120.19M
- P/E (TTM)
- –
- Dividend yield
- –
CODEXIS, INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novel Biotherapeutics | – | – | – | – | – | – | $10.30M | $13.52M | $7.69M | – | – | – |
| Performance Enzymes | – | – | – | – | – | – | $58.16M | $47.07M | $42.33M | – | – | – |
| Performance Enzymes | – | – | – | $126.61M | $90.52M | $48.11M | $58.16M | $47.07M | $42.33M | – | – | – |
| Novel Biotherapeutics | – | – | – | $11.98M | $14.24M | $20.95M | $10.30M | $13.52M | – | – | – | – |
| Novel Biotherapeutics | – | – | – | – | – | – | – | $13.52M | $7.69M | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Novel Biotherapeutics | – | – | – | – | – | – | -$5.20M | $2.57M | -$4.42M | – | – |
| Performance Enzymes | – | – | – | – | – | – | $14.68M | $7.99M | $3.79M | – | – |
| Performance Enzymes | – | – | – | $46.36M | $33.06M | $3.84M | $14.68M | $7.99M | – | – | – |
| Novel Biotherapeutics | – | – | – | -$41.18M | -$18.74M | -$3.11M | -$5.20M | $2.57M | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development revenue | $44.36M | $22.56M | $27.24M | – | – | – | – | – | – | – | 63.0% | +96.6% |
| Product revenue | $26.03M | $36.79M | $42.91M | $116.68M | $70.66M | – | – | – | – | – | 37.0% | -29.2% |
| Product revenue | – | – | – | $116.68M | $70.66M | $30.22M | $29.47M | $25.59M | $26.69M | $15.32M | – | – |
| Research and development revenue ($1,955, $900 and $0 from a related party) | – | – | – | – | $34.10M | $38.84M | $38.99M | $35.00M | $23.34M | $33.52M | – | – |
| Research and development revenue | – | $22.56M | $27.24M | $21.91M | $34.10M | $38.84M | $38.99M | $35.00M | $23.34M | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $43.54M | $21.28M | $13.73M | $17.00M | $23.48M | $24.35M | $13.04M | $15.37M | $15.58M | $23.13M | 61.9% | +104.6% |
| United States | $43.50M | $21.30M | $13.70M | $17.00M | $23.40M | – | – | – | $15.47M | $21.31M | 61.8% | +104.2% |
| APAC | $17.56M | $27.71M | $33.50M | $65.05M | $61.09M | $25.45M | $18.29M | – | – | – | 24.9% | -36.6% |
| China | $9.30M | $9.80M | $20.30M | $48.60M | $43.50M | – | – | – | – | – | 13.2% | -5.1% |
| EMEA | $9.29M | $10.36M | $22.91M | $56.54M | $20.19M | $19.26M | $37.13M | $22.36M | $19.61M | $17.14M | 13.2% | -10.3% |
| India | $5.70M | $7.30M | $5.70M | $8.80M | – | – | – | – | $5.64M | $3.58M | 8.1% | -21.9% |
| Switzerland | $4.20M | $3.40M | $11.10M | $9.20M | $10.10M | – | – | – | $13.22M | $2.32M | 6.0% | +23.5% |
| Ireland | $700.00K | $1.80M | $500.00K | $37.20M | $1.40M | – | – | – | – | – | 1.0% | -61.1% |
| Singapore | $400.00K | $6.20M | $2.40M | $3.20M | – | – | – | – | $6.17M | $3.84M | 0.6% | -93.5% |
| Europe | – | – | – | – | – | – | – | – | – | $17.14M | – | – |
| Others | – | – | – | – | – | – | – | – | – | $1.82M | – | – |
| Other Asian Countries [Member] | – | – | – | – | – | – | – | – | – | $1.16M | – | – |
| United Kingdom | – | – | – | – | – | – | – | – | $51.00K | $10.85M | – | – |
| Rest of world | – | – | – | – | – | – | – | – | $9.48M | $6.95M | – | – |
| APAC | – | – | – | – | – | $25.45M | $18.29M | $22.86M | $14.84M | $8.57M | – | – |
From the segment and revenue-disaggregation notes of Codexis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.